

Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Mr Craig Thomsen Director, Regulatory Affairs and Quality Assurance Eurofins Donor & Product Testing Inc 1700 Enterprise Way Suite 144 Marietta Georgia 30067 United States of America

TGA Reference: E18-367553

Subject: Issue of GMP certificate MI-2021-CE-03634-1

Dear Mr Thomsen,

Please find enclosed the GMP certificate for your manufacturing premises.

The certificate remains valid only if re-inspections are conducted when scheduled by the Therapeutic Goods Administration. The inspection frequency is not a reflection of the expiry date shown on the certificate but is consistent with the re-inspection frequency applicable to Australian manufacturers of the same class of products.

The Therapeutic Goods Administration will contact the relevant sponsor/s to arrange the re-inspection of your facility.

Yours sincerely,

Signed and authorised by

Jenny Hantzinikolas Director, Inspectorate Section Manufacturing Quality Branch

19 August 2022

Contact: GMP@health.gov.au, Phone: 1800 020 653





Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Certificate of GMP Compliance of a Manufacturer

Certificate Number:

MI-2021-CE-03634-1

Issued to:

Eurofins Donor & Product Testing Inc

Manufacturing Site Address:

1700 Enterprise Way Suite 144 Marietta Georgia 30067 United States of America

The Therapeutic Goods Administration, the Competent Authority of Australia, confirms that this manufacturer has been inspected following Section 32EA(1) of the *Therapeutic Goods Act 1989* in connection with manufacturers of Biologicals (items made from or containing human cells or human tissues) located outside Australia.

This certificate is issued based on a remote inspection of GMP compliance during COVID-19 travel restrictions. From the knowledge gained during inspection of this manufacturer, the latest of, that was conducted on 20 to 23 September 2021, it is considered that the manufacturer complies with the Good Manufacturing Practice (GMP) requirements of the Australian Code of Good Manufacturing Practice for Human Blood and Blood Components, Human Tissues and Human Cellular Therapy Products (2013).

This certificate reflects the status of the manufacturing site at the time of the inspection noted above. This certificate remains valid until the expiry date provided that re-inspections are conducted as determined by the Therapeutic Goods Administration as the issuing Authority. This certificate should not be relied upon to reflect the compliance status after the expiry date.

Issue Date: 19 August 2022 Expiry Date: 23 September 2023

This certificate remains valid only if re-inspections are conducted when scheduled by the Therapeutic Goods Administration. The authenticity of this certificate may be verified with the Therapeutic Goods Administration as the issuing authority.



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Certificate of GMP Compliance of a Manufacturer

Certificate Number:

MI-2021-CE-03634-1

MANUFACTURING OPERATIONS

This certificate covers the following steps in the manufacture of therapeutic goods at the manufacturing site address specified above.

Manufacturing Type	Manufacturing Step
Testing Laboratory - Blood Tissue Cellular	Virology Screening and Syphilis Testing
	NAT Testing

The following limitations are applicable to these manufacturing operations:

NAT testing is restricted to HIV-I/II, HCV, HBV and West Nile Virus (WNV).

This certificate remains valid only if re-inspections are conducted when scheduled by the Therapeutic Goods Administration. The authenticity of this certificate may be verified with the Therapeutic Goods Administration as the issuing authority.